These results indicate that EphB4 is a predictor of the therapeutic efficacy of osimertinib and of the subsequent clinical outcomes of patients with EGFR mutation-positive lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.